<div id=toc></div>

# Table of Contents

- [q-bio.QM](#q-bio.QM) [Total: 1]


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [1] [Multiscale Cross-Modal Mapping of Molecular, Pathologic, and Radiologic Phenotypes in Lipid-Deficient Clear Cell Renal CellCarcinoma](https://arxiv.org/abs/2512.14750)
*Ying Cui,Dongzhe Zheng,Ke Yu,Xiyin Zheng,Xiaorui Wang,Xinxiang Li,Yan Gu,Lin Fu,Xinyi Chen,Wenjie Mei,Xin-Gui Peng*

Main category: q-bio.QM

TL;DR: 开发了一个跨尺度框架，通过病理和放射学模型术前识别透明细胞肾细胞癌的脂质缺乏去透明细胞分化亚型，实现分子表型预测和临床风险分层。


<details>
  <summary>Details</summary>
Motivation: 透明细胞肾细胞癌存在显著的瘤内异质性，传统TNM分期效果有限，特别是脂质缺乏去透明细胞分化亚型即使在早期疾病中也与不良预后相关，迫切需要多尺度整合分析框架进行术前识别。

Method: 建立了分层跨尺度框架：通过跨模态映射将分子特征转移到组织学和CT表型；PathoDCCD模型捕获多尺度微观特征（细胞形态、组织结构、区域组织）；RadioDCCD模型整合宏观信息（全肿瘤和栖息地亚区域影像组学+2D最大切面异质性指标）。

Result: 在5个队列共1,659名患者中，PathoDCCD可靠地再现了分子亚型，RadioDCCD提供了可靠的术前预测；一致的预测识别了临床结局最差的患者群体。

Conclusion: 该跨尺度范式将分子生物学、计算病理学和定量放射学统一为基于生物学的策略，实现了透明细胞肾细胞癌的术前无创分子表型分析。

Abstract: Clear cell renal cell carcinoma (ccRCC) exhibits extensive intratumoral heterogeneity on multiple biological scales, contributing to variable clinical outcomes and limiting the effectiveness of conventional TNM staging, which highlights the urgent need for multiscale integrative analytic frameworks. The lipid-deficient de-clear cell differentiated (DCCD) ccRCC subtype, defined by multi-omics analyses, is associated with adverse outcomes even in early-stage disease. Here, we establish a hierarchical cross-scale framework for the preoperative identification of DCCD-ccRCC. At the highest layer, cross-modal mapping transferred molecular signatures to histological and CT phenotypes, establishing a molecular-to-pathology-to-radiology supervisory bridge. Within this framework, each modality-specific model is designed to mirror the inherent hierarchical structure of tumor biology. PathoDCCD captured multi-scale microscopic features, from cellular morphology and tissue architecture to meso-regional organization. RadioDCCD integrated complementary macroscopic information by combining whole-tumor and its habitat-subregions radiomics with a 2D maximal-section heterogeneity metric. These nested models enabled integrated molecular subtype prediction and clinical risk stratification. Across five cohorts totaling 1,659 patients, PathoDCCD reliably recapitulated molecular subtypes, while RadioDCCD provided reliable preoperative prediction. The consistent predictions identified patients with the poorest clinical outcomes. This cross-scale paradigm unifies molecular biology, computational pathology, and quantitative radiology into a biologically grounded strategy for preoperative noninvasive molecular phenotyping of ccRCC.

</details>
